Alphamab Oncology (9966.HK)
| Previous close | 5.100 |
| Open | 5.170 |
| Bid | 5.270 x N/A |
| Ask | 5.300 x N/A |
| Day's range | 5.150 - 5.880 |
| 52-week range | 3.810 - 13.460 |
| Volume | |
| Avg. volume | 2,528,815 |
| Market cap | 5.114B |
| Beta (5Y monthly) | 0.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.240 |
| Earnings date | 28 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.01 |
PR NewswireAlphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting
Alphamab Oncology (stock code: 9966.HK) announced that data from the clinical study conducted in China (JSKN003-102) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, will be presented for the first time at the 2024 Annual Meeting of American Society of Clinical Oncology (2024 ASCO Annual Meeting) from May 31 to June 4, 2024, in Chicago, IL, U.S..
PR NewswireAlphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR
Alphamab Oncology (stock code: 9966.HK) announced the data from phase I clinical study conducted in Australia (JSKN003-101) of anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 for the treatment of HER2-expressing advanced solid tumors, were presented as a poster at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024).
PR NewswireAlphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights
Alphamab Oncology (stock code: 9966.HK) reported financial results for the full year ended December 31, 2023 and highlighted recent progress and upcoming milestones.
